O1-01-05: Long-term use of angiotensin receptor blockers and risk of Alzheimer's disease in a cohort of patients with hypertension

2010 ◽  
Vol 6 ◽  
pp. S69-S69
Author(s):  
Rachel A. Whitmer ◽  
Peter Zandi ◽  
Charles P. Quesenberry ◽  
Jufen Zhou ◽  
Benjamin Wolozin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers

Do Angiotensin Receptor Blockers Protect Against Alzheimer’s Disease?

Drugs & Aging ◽  
2013 ◽  
Vol 30 (6) ◽  
pp. 367-372 ◽  
Author(s):  
Hitomi Kurinami ◽  
Munehisa Shimamura ◽  
Naoyuki Sato ◽  
Hironori Nakagami ◽  
Ryuichi Morishita
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers

scholarly journals Role of antihypertensive drugs in the treatment of migraine

2015 ◽  
Vol 156 (5) ◽  
pp. 179-185 ◽  
Author(s):  
Gergely Fehér ◽  
Gabriella Pusch
Keyword(s):  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Channel Blockers ◽  
Migraine Prevention ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Receptor Blockers

The treatment of migraine depends on the frequency, severity and concomitant diseases. There are several specific drugs developed for migraine prevention in addition to the additive antimigraine effects of some other non-specific drugs. The aim of this literature-based review is to summarize the possible antimigraine properties of different antihypertensive agents (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc.) focusing on the possible side effects (avoidance of beta blockers in the absence of heart disease, possible antiparkinson effect of calcium channel blockers, additive effect of drugs modifying the renin-angiotensin system activity, etc.). Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly lisinopril) and angiotensin receptor blockers (mainly candesartan) for long-term migraine prevention and blood pressure control. Long-term beta-blocker treatment should be avoided in the absence of ischemic heart disease due to possible unfavourable cardiovascular effects. Orv. Hetil., 2015, 156(5), 179–185.

scholarly journals Sartans in the treatment of high-risk hypertension: the abilities of candesartan

2013 ◽  
Vol 10 (2) ◽  
pp. 13-18
Author(s):  
T E Morozova
Keyword(s):  
Heart Failure ◽  
High Risk ◽  
High Efficiency ◽  
Antihypertensive Effect ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Hypertensive Patients ◽  
Receptor Blockers ◽  
Good Range

This paper presents an overview of the literature on the treatment of arterial hypertension drugs that block the renin-angiotensin-aldosterone system (RAAS) – angiotensin receptor blockers ΙΙ (ARB), whose action is based on inhibition of the RAAS at the AII receptor. ARB candesartan (atakand), along with a strong long-term antihypertensive effect has organoprotective (causes regression of LVH has nephroprotection) antidiabetogennym effect, prevents the development of stroke. Clinical experience suggests candesartan, high efficiency and a good range of security among different categories of hypertensive patients with concomitant pathology, chronic heart failure, diabetes, obesity.

scholarly journals Long-Term Use of Angiotensin Receptor Blockers and the Risk of Cancer

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e50893 ◽  
Author(s):  
Laurent Azoulay ◽  
Themistocles L. Assimes ◽  
Hui Yin ◽  
Dorothee B. Bartels ◽  
Ernesto L. Schiffrin ◽  
...  
Keyword(s):  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers ◽  
Risk Of Cancer
Sign in / Sign up

Export Citation Format

Share Document